FibroGen Inc (FGEN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:FibroGen Inc (FGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013981
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney disease; FG-3019, a monoclonal antibody developed to treat duchenne muscular dystrophy, idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. Its roxadustat is supported by extensive clinical data demonstrating correction and maintenance of hemoglobin levels in multiple subpopulations of CKD anemia patients. The company conducts research and development in the fields of connective tissue growth factor and hypoxia-inducible factor. FibroGen is headquartered in San Francisco, California, the US.

FibroGen Inc (FGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
FibroGen Inc, Medical Devices Deals, 2011 to YTD 2017 10
FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
FibroGen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 12
Equity Offering 13
FibroGen Prices Public Offering of Shares for USD326 Million 13
FibroGen Raises USD120 Million in Public Offering of Shares 14
FibroGen Raises USD168 Million in IPO of Shares 16
FibroGen to Raise USD20 Million in Private Placement of Shares 18
FibroGen Inc – Key Competitors 20
FibroGen Inc – Key Employees 21
FibroGen Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 08, 2017: FibroGen Reports Third Quarter 2017 Financial Results 23
Aug 07, 2017: FibroGen Reports Second Quarter 2017 Financial Results 25
May 09, 2017: FibroGen Reports First Quarter 2017 Financial Results 26
Mar 01, 2017: FibroGen Reports Fiscal 2016 Financial Results 27
Nov 08, 2016: FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update 28
Aug 08, 2016: FibroGen Reports Financial Results for the Second Quarter of 2016 29
May 09, 2016: FibroGen Reports Financial Results for the First Quarter of 2016 30
Feb 29, 2016: FibroGen Announces Fiscal 2015 Financial Results 31
Corporate Communications 32
Sep 19, 2017: FibroGen Appoints Gerald Lema to Board of Directors 32
Product News 33
06/09/2016: Fibrogen Announces Initiation By Astellas Of Phase 3 Clinical Study In Japan Of Roxadustat/ASP1517 For The Treatment Of Anemia Of Chronic Kidney Disease Triggering $10.0 Million Milestone Payment 33
03/31/2017: FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS 34
Clinical Trials 35
Mar 30, 2017: Positive Results Published in Nephrology Dialysis Transplantation From Two China Phase 2 Trials of Roxadustat for Treatment of Anemia in Chronic Kidney Disease 35
Jan 30, 2017: FibroGens Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China 36
Oct 31, 2016: FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China 38
Aug 05, 2016: CDSCO Announces Approval of protocol for enrollment of 130 additional subjects in India 39
Jul 25, 2016: Astellas And Fibrogen Announce First Patient Treated In Phase 3 Studies And Positive Phase 2 Results Of Roxadustat In Patients With Chronic Kidney Disease In Japan 40
Apr 20, 2016: Promising Phase 2 Data Show Roxadustat Corrected Anemia In Chronic Kidney Disease Patients Before Intervention With Dialysis 42
Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis 43
Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat’s Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease 45
Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer 47
Jan 06, 2016: FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
FibroGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
FibroGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
FibroGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
FibroGen Inc, Deals By Therapy Area, 2011 to YTD 2017 9
FibroGen Inc, Medical Devices Deals, 2011 to YTD 2017 10
FibroGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 12
FibroGen Prices Public Offering of Shares for USD326 Million 13
FibroGen Raises USD120 Million in Public Offering of Shares 14
FibroGen Raises USD168 Million in IPO of Shares 16
FibroGen to Raise USD20 Million in Private Placement of Shares 18
FibroGen Inc, Key Competitors 20
FibroGen Inc, Key Employees 21
FibroGen Inc, Subsidiaries 22

★海外企業調査レポート[FibroGen Inc (FGEN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • New Enterprise Associates Inc:企業のM&A・事業提携・投資動向
    New Enterprise Associates Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Enterprise Associates Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Imbed Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Imbed Biosciences Inc (Imbed) is a medical device company which develops technologies for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. The company’s product platform, a polymeric Microfilm develops bioactive molecules on tissue surfaces to manage wou …
  • Bukwang Pharmaceutical Co Ltd (003000):企業の財務・戦略的SWOT分析
    Summary Bukwang Pharmaceutical Co Ltd (Bukwang Pharmaceutical) is a pharmaceutical company that develops new drugs and pharmaceutical products. The company’s products portfolio includes dexide, chioctaside, levovir, orfil, lonacene, axima, and excel, among others. Its pipeline products comprise JM-0 …
  • Impresa Pizzarotti & C. S.p.A.:企業の戦略・SWOT・財務情報
    Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Impresa Pizzarotti & C. S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Bet Shemesh Engines Holdings (1997) Ltd:企業の戦略・SWOT・財務情報
    Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report Summary Bet Shemesh Engines Holdings (1997) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Bio-Rad Laboratories, Inc.:企業の戦略・SWOT・財務情報
    Bio-Rad Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bio-Rad Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • NTT Communications Corporation:企業の戦略・SWOT・財務情報
    NTT Communications Corporation - Strategy, SWOT and Corporate Finance Report Summary NTT Communications Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Genesis Energy Ltd (GNE):企業の財務・戦略的SWOT分析
    Genesis Energy Ltd (GNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Solargiga Energy Holdings Ltd (757):電力:M&Aディール及び事業提携情報
    Summary Solargiga Energy Holdings Ltd (Solargiga Energy), a subsidiary of Wafer Works Corp is a renewable energy equipment manufacturer that develops and markets monocrystalline silicon products. The company manufactures monocrystalline silicon solar ingots and wafers, solar cells and photovoltaic m …
  • Japan Exchange Group Inc:企業の戦略・SWOT・財務情報
    Japan Exchange Group Inc - Strategy, SWOT and Corporate Finance Report Summary Japan Exchange Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Vast Resources Plc:企業の戦略・SWOT・財務情報
    Vast Resources Plc - Strategy, SWOT and Corporate Finance Report Summary Vast Resources Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • CSI Compressco LP (CCLP):石油・ガス:M&Aディール及び事業提携情報
    Summary CSI Compressco LP (CSI), formerly Compressco Partners LP, a subsidiary of TETRA Technologies Inc, is an oilfield consulting company that offers compression services and equipment for natural gas and oil production, transportation, and storage. The company's products include real-time compres …
  • AGRANA Beteiligungs-AG:企業の戦略・SWOT・財務分析
    AGRANA Beteiligungs-AG - Strategy, SWOT and Corporate Finance Report Summary AGRANA Beteiligungs-AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • AGA Rangemaster Group Ltd:企業の戦略的SWOT分析
    AGA Rangemaster Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Young & Co.’s Brewery, P.L.C. (YNGA):企業の財務・戦略的SWOT分析
    Young & Co.'s Brewery, P.L.C. (YNGA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • KITCO Fiber Optics, Inc.:企業の戦略・SWOT・財務情報
    KITCO Fiber Optics, Inc. - Strategy, SWOT and Corporate Finance Report Summary KITCO Fiber Optics, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Theranostics Health Inc-製薬・医療分野:企業M&A・提携分析
    Summary Theranostics Health Inc (Theranostics), a subsidiary of Avant Diagnostics Inc is a healthcare service provider that offers protein based solutions. The company provides protein based discovery and translational research services. Its products include molecular navigation of targeted therapie …
  • Chattem Inc:企業の戦略・SWOT・財務情報
    Chattem Inc - Strategy, SWOT and Corporate Finance Report Summary Chattem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • CSE Global Ltd (544):石油・ガス:M&Aディール及び事業提携情報
    Summary CSE Global Limited (CSE) is a technology company offering process control systems and integrated plant communication systems. It’s process control systems offers emergency shutdown systems, process shutdown systems, integrated control & safety systems and fire and gas detection systems, well …
  • Azure Power India Private Limited (AZRE)-エネルギー分野:企業M&A・提携分析
    Summary Azure Power India Private Limited (Azure) is a renewable energy company that offers solar products. The company designs, installs, produces, finances, owns and operates solar power plants. Its services include engineering, operational performance monitoring, and others. Azure provides off gr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆